Neha Krishnamohan's most recent trade in Arcutis Biotherapeutics Inc was a trade of 20,568 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 20,568 | 20,568 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 7,609 | 23,355 (0%) | 0% | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Neha Krishnamohan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 60,000 | 110,000 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Neha Krishnamohan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 50,000 | 50,000 | - | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 27,052 | 27,052 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 10,139 | 15,746 (0%) | 0% | 0 | Common Stock | |
| Kinnate Biopharma Inc | Neha Krishnamohan | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.59 per share. | 01 Mar 2024 | 1,506 | 64,087 | - | 2.6 | 3,901 | Common Stock |
| Kinnate Biopharma Inc | Krishnamohan Neha | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.25 per share. | 01 Dec 2023 | 1,459 | 65,593 | - | 2.3 | 3,283 | Common Stock |
| Kinnate Biopharma Inc | Neha Krishnamohan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.30 per share. | 01 Jun 2023 | 1,459 | 68,511 | - | 4.3 | 6,274 | Common Stock |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 12,220 | 12,220 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 4,375 | 5,607 (0%) | 0% | 0 | Common Stock | |
| Kinnate Biopharma Inc | Neha Krishnamohan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.21 per share. | 01 Mar 2023 | 1,721 | 67,378 | - | 5.2 | 8,966 | Common Stock |
| Kinnate Biopharma Inc | Neha Krishnamohan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 215,000 | 215,000 | - | - | Employee Stock Option (right to buy) | |
| Kinnate Biopharma Inc | Neha Krishnamohan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.75 per share. | 01 Dec 2022 | 1,459 | 69,099 | - | 7.7 | 11,307 | Common Stock |
| Arcutis Biotherapeutics Inc | Neha Krishnamohan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2022 | 29,482 | 29,482 | - | - | Stock Option (Right to Buy) | |
| Kinnate Biopharma Inc | Neha Krishnamohan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 67,500 | 69,015 | - | 0 | Common Stock | |
| Kinnate Biopharma Inc | Neha Krishnamohan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 185,000 | 185,000 | - | - | Employee Stock Option (right to buy) | |
| Kinnate Biopharma Inc | Neha Krishnamohan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 270,000 | 270,000 | - | - | Employee Stock Option (right to buy) |